Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61B AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315461METHODS OF DIAGNOSING AND TREATING VIRAL INFECTIONS
US 14.10.2021
Int.Class A61B 5/01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
01Measuring temperature of body parts
Appl.No 17229185 Applicant Ibrahim Saud ALMISHARI Inventor Ibrahim Saud ALMISHARI

Diagnosing and treating viral infections. One example is a method of diagnosing absence of severe acute respiratory syndrome 2 (SARS-CoV-2), the method including: isolating a human in a covid-free environment for an isolation period; performing measurements of a core temperature during the isolation period; and if each of the measurements of the core temperature indicate a lack of fever, declaring the human free of SARS-CoV-2. Another example is a method including treating coronavirus in a human by: receiving a core temperature measurement; receiving a test result regarding the SARS-CoV-2 virus; responsive to the human having both fever and the presence of the SARS-CoV-2 virus, submerging the trunk and the legs of the human in water with a surfactant, and the human at least partially submerged for a treatment period of at least three hours; and controlling a temperature of the water during the treatment period.

2.WO/2021/243372CLOSED-LOOP ANTIMICROBIAL PHOTO-PLASMAPHERESIS
WO 02.12.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
Appl.No PCT/US2021/070633 Applicant BAYLOR COLLEGE OF MEDICINE Inventor SZIGETI, Reka
The present disclosure concerns systems and methods related to the treatment, prevention, delay of onset, or reduction of severity of a microbial infection in an individual, including closed-loop plasmapheresis and extracorporeal light irradiation of the plasma of the individual. The systems and methods further relate to irradiation of the plasma of the individual with UV and/or visible light, optionally in the presence of a photosensitizer. The systems and methods further relate to light irradiation inactivation of microbial particles in the plasma taken from the individual. The systems and methods further relate to the optional filtration of microbial particles from UV light-treated plasma. The systems and methods further relate to reinfusion of the UV light-treated, optionally filtered, plasma back into the individual. The systems and methods further relate to treating, preventing, delaying onset of, or reducing in severity a viral infection, particularly a viral infection caused by a Coronaviridae family virus, at least including SARS-CoV-2. The systems and methods are further configured to reduce viral load and/or lymphocyte reinfection rate in the individual.
3.WO/2021/247682METHODS FOR MITIGATING OR DIMINISHING SPREAD OF PATHOGENIC INFECTIONS
WO 09.12.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No PCT/US2021/035421 Applicant ROSS, Peter M. Inventor ROSS, Peter M.
The present methods comprise initial administration of a first rapid test, such as rapid antigen test, that has a low likelihood of false positive results and a known likelihood of false negative results, alone or in conjunction with other rapid tests, to identify a first subpopulation of positives, to which an infection mitigation protocol (such as quarantine or the administration of a therapeutic treatment) is administered. Negatives are recorded and provisionally released from further study. A diagnostic test is then administered to this subpopulation, to identify the portion of this first subpopulation that were false positives in the first test. Ideally, a positive result for the diagnostic test is pathognomonic for the infection. Any infection mitigation protocol (such as quarantine) may then be discontinued for those testing negative in the first population and intensified for those testing positive, such as with contact tracing or other protocols, to identify all true positives and those they may have infected within the population.
4.WO/2021/222237DETECTION OF VIRUSES IN FACEMASKS
WO 04.11.2021
Int.Class A61B 5/097
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
08Measuring devices for evaluating the respiratory organs
097Devices for facilitating collection of breath or for directing breath into or through measuring devices
Appl.No PCT/US2021/029384 Applicant CAMAS INCORPORATED Inventor SIMPLOT, Scott
Facemasks with an integrated virus detection system are described. The virus detection system is embedded in or on a facemask worn by an individual susceptible to a viral infection. The individual wears a facemask for protective purposes during work or leisure. If the individual develops a viral infection and begins discharging viral particles from mouth and/or nose, the virus detection system embedded in the facemask retains the virus particles. The virus particles are detected in an immunoassay. The virus particles in the virus detection system embedded in the facemask are detected by avian antibodies. The virus detection system in the facemask is configured to detect one or more viruses, for example, SARS-CoV-2.
5.WO/2021/178574METHODS AND SYSTEMS FOR NITRIC OXIDE THERAPY FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS
WO 10.09.2021
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
Appl.No PCT/US2021/020725 Applicant KNOW BIO, LLC Inventor STASKO, Nathan
Methods for the treatment of a. respiratory infection, for the prevention of worsening of symptoms associated, with the infection, and for reducing the lethality of the infection such as bin not limited to respiratory infections caused by a coronavirus. The present disclosure provides specific gaseous nitric oxide (NO) dosing regimens optionally paired with the monitoring of toxicology outcomes so as to enable the use of effective NO doses for treatment purposes. The present invention also discloses air circulation systems featuring NO for helping to prevent respiratory infections.
6.20210315925METHODS OF TREATING VIRAL INFECTIONS
US 14.10.2021
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No 16848055 Applicant Ibrahim Saud ALMISHARI Inventor Ibrahim Saud ALMISHARI

Methods of treating viral infections. At least one example embodiment is a method including: measuring a core temperature of a human patient; testing the human for the presence of a virus that causes disease; responsive to the human having both fever and presence of the virus, submerging at least a trunk and legs of the human in water comprising a surfactant, the human at least partially submerged in the water for a treatment period of at least three hours; and controlling a temperature of the water during the treatment period.

7.WO/2021/207184USE OF INHALED NITRIC OXIDE (iNO) FOR TREATMENT OF INFECTION, INCLUDING INFECTION WITH SARS-CoV2 AND TREATMENT OF COVID-19
WO 14.10.2021
Int.Class A61B 5/087
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
08Measuring devices for evaluating the respiratory organs
087Measuring breath flow
Appl.No PCT/US2021/025950 Applicant BELLEROPHON THERAPEUTICS Inventor SHAH, Parag
The present disclosure relates to use of pulsed dose inhaled nitric oxide for treatment of infection, including infection with SARS-CoV2 and the disease state COVID-19.
8.2020102382AN ARTIFICIAL INTELLIGENCE BASED SYSTEM FOR COVID PREVENTION
AU 08.10.2020
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
Appl.No 2020102382 Applicant Bhasin, Narinder Kumar DR Inventor
The present invention relates to an artificial intelligence based system for COVID prevention. The proposed invention incorporates a definite number of subsystems each enabling checks and/or preventive actions against the most obvious symptoms of coronavirus. The invention has to be deployed at the entry point of the place of human assembly restricts the virus-infected people from entering the premise
9.2021102333AN UTILIZATION OF ARTIFICIAL INTELLIGENCE BASED SYSTEM FOR PREVENTING COVID EFFECT ON HUMAN BODY
AU 20.05.2021
Int.Class A61B 5/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
08Measuring devices for evaluating the respiratory organs
Appl.No 2021102333 Applicant G., Pavithra DR Inventor
AN UTILIZATION OF ARTIFICIAL INTELLIGENCE BASED SYSTEM FOR PREVENTING COVID EFFECT ON HUMAN BODY The present invention relates to a utilization of artificial intelligence based system for preventing covid effect on human body. The proposed invention incorporates a definite number of subsystems each enabling checks and/or preventive actions against the most obvious symptoms of coronavirus. The invention has to be deployed at the entry point of the place of human assembly restricts the virus-infected people from entering the premise
10.20220008276Pressure Differential-, Ultrasound-, and Magnetic-Based Methods for Treating Viral Infections and other Pathogenic Diseases, Sterilizing Medical Equipment, and Enhancing Fatty Tissue Reduction
US 13.01.2022
Int.Class A61G 10/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
GTRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
10Treatment rooms for medical purposes
02with artificial climate; with means to maintain a desired pressure, e.g. for germ-free rooms
Appl.No 17369803 Applicant Gabriel Curiel Inventor Gabriel Curiel

The present disclosure is directed to methods of treating subject patients (such as humans, animals, plants) suffering from a pathogenic disease such as COVID-19 in humans, via the administration of pressure changes in the patient sufficient to cause a pressure differential to be created between the inside and outside of the outer membrane or envelope of the pathogen thereby destroying or disabling the pathogen. In one embodiment, a hyperbaric chamber is used to administer pressure increases and/or pressure decreases to create such pressure differential. The hyperbaric chamber could comprise a single user or multi-user unit, a pressurized body suit, or the pressurizable fuselage of an aircraft. In another embodiment, patients are placed in an aircraft, and the cabin pressure, while on the ground, or in flight, is adjusted upwardly or downwardly to create such pressure differential. The pressure differential methods can also include the use of external gases to enter the patient's body and/or lungs to facilitate disruption of the pathogen outer membrane as well as application of variations in temperature and/or humidity. A mobile treatment unit is also disclosed. Also disclosed are methods of using ultrasonic cavitation or MRI (or other sonic or magnetic field forces sufficient to disrupt the functionality of the pathogen), or a combination of ultrasound and MRI on the exterior of a patient in a desired anatomical region of the patient to assist with the destruction or disabling of a pathogen infecting that anatomical region of the patient, e.g., the patient's lungs, said method being employed at ambient pressures or in an increased or decreased pressure environment created within a hyperbaric chamber. The ultrasound and/or MRI methodologies could also be used to treat other pathogenically afflicted areas of the patient's body. Additionally, a pressure-differential method of sterilization of medical equipment is disclosed employing a hyperbaric or other pressure or vacuum chamber. Also disclosed is an enhanced method of nonsurgical fat reduction in humans by employing ultrasonic cavitation within a hyperbaric chamber, including the use of HBOT therapies. Furthermore, the use of these methodologies and systems have application in treatment of patients post-infection and in other areas of medicine and health, such as for example, treating wounds, the effects of aging, inflammation, and the effects of other maladies.